In the present work, fast dissolving tablets of pioglitazone were prepared by direct compression method with a view to enhance patient compliance. Two superdisintegrants viz, crospovidone and croscarmellose sodium with different concentration were used. The prepared batches of tablets were evaluated for hardness, friability, weight variation, disintegration, wetting time, drug content and in vitro dissolution studies. Based on evaluating parameters, formulation prepared by using croscarmellose sodium and crospovidone were selected as optimized formulation. Finally, the optimized formulation was compared with marketed conventional formulation. Pioglitazone is a prescription drug of the class thiazolidinedione with hypoglycemic (antihyperglycemic, anti diabetic) action. Pioglitazone reduces insulin resistance in the liver and peripheral tissues; increases the expense of insulin-dependent glucose; decreases withdrawal of glucose from the liver; reduces quantity of glucose, insulin and glycated haemoglobin in the bloodstream. Following oral administration, in the fasting state, pioglitazone is first measurable in serum within 30 minutes, with peak concentrations observed within 2 hours. Food slightly delays the time to peak serum concentration to 3 to 4 hours, but does not alter the extent of absorption.
Fast Dissolving Tablets, Pioglitazone, Superdisintegrants, Direct Compression
